Medical academic journalMedical academic journal1608-41012687-1378Eco-Vector10852110.17816/MAJ108521Conference Report, Theses of ReportThe severity of COVID-19 is accompanied by a change in the expression of the surface marker CD38 in T lymphocytes and NK cellsVavilovaJulia D.<p>Junior Research Associate</p>juliateterina12@gmail.comhttps://orcid.org/0000-0002-9075-218XBoykoAnna A.<p>Cand. Sci. (Biol.), Research Associate</p>boyko_anna@mail.ruhttps://orcid.org/0000-0002-8996-2905StreltsovaMaria A.<p>Cand. Sci. (Biol.), Research Associate</p>mstreltsova@mail.ruhttps://orcid.org/0000-0002-5403-0753KustSofya A.<p>Cand. Sci. (Biol.), Junior Research Associate</p>sonya.erokhina@gmail.comhttps://orcid.org/0000-0001-6365-0279YusubalievaGaukhar M.<p>MD, Cand. Sci. (Med.), Senior Research Associate</p>gaukhar@gaukhar.orghttps://orcid.org/0000-0003-3056-4889NovikovaOksana N.<p>MD, Cand. Sci. (Med.), Head of the Therapeutic Department</p>Novikova_oksana_@mail.ruhttps://orcid.org/0000-0003-2779-0383SotnikovaAnna G.<p>MD, Cand. Sci. (Med.), Head of the Department of Pulmonology</p>sotnikoffaa@gmail.comBychininMikhail V.<p>MD, Cand. Sci. (Med.), Head of the Department of Resuscitation and Intensive Care</p>drbychinin@gmail.comhttps://orcid.org/0000-0001-8461-4867IschakovRustam N.<p>Student</p>Rustam110798Rus@gmail.comSapozhnikovAlexander M.<p>Dr. Sci. (Biol.), Professor, Head of the Laboratory of Cellular Interactions</p>amsap@mail.ruhttps://orcid.org/0000-0002-4934-677XKovalenkoElena I.<p>Cand. Sci. (Biol.), Senior Research Associate</p>lenkovalen@mail.ruhttps://orcid.org/0000-0001-8119-8247Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of SciencesFederal Research and Clinical Center of Specialized Medical Care and Medical Technologies FMBA of Russia061120222221491560306202221072022Copyright © 2022, Eco-Vector2022<p><strong><em>BACKGROUND:</em></strong> COVID-19 mediates activation of immunocompetent cells. Little is known about the phenotypic marker CD38 on the surface of T and NK cells and its association with the severity of COVID-19.</p>
<p><strong><em>AIM:</em></strong> To analyze the distribution of the surface marker CD38 in subsets of T and NK cells at the different stages of their differentiation in the groups of patients with COVID-19 and convalescents, and to reveal the relationship between the level of CD38 expression in subpopulations of T and NK cells with the severity of COVID-19.</p>
<p><strong><em>MATERIALS AND METHODS:</em></strong> Peripheral blood mononuclear cells (PBMC) from patients and donors were isolated using ficoll density gradient followed by cytofluorimetric analysis of the surface markers: CD3, CD56, CD38.</p>
<p><strong><em>RESULTS:</em></strong> In PBMC samples the level of CD38 expression on NK cells (CD3<sup></sup>CD56<sup>+</sup>), including CD56<sup>bright</sup> and CD56<sup>dim</sup> subsets, as well as on T lymphocytes, differentiating conventional CD56<sup></sup>(CD3<sup>+</sup>CD56<sup></sup>) and NKT-like (CD3<sup>+</sup>CD56<sup>+</sup>) cells, were analyzed. Among CD56<sup></sup> T cells and NKT-like cells the highest levels of CD38 expression were registered in the groups of patients of moderate severity and convalescents, and, in contrast, the decreased CD38 levels were detected in the group of patients from the intensive care unit.</p>
<p><strong><em>CONCLUSIONS:</em></strong> The findings suggest that the level of CD38<sup>+</sup> T cell in COVID-19 may be of use as diagnostic value.</p>COVID-19T-lymphocytesNK cells, CD38COVID-19T-лимфоцитыNK-клетки, CD38[Abdullaev A, Odilov A, Ershler M, et al. Viral load and patterns of SARS-CoV-2 dissemination to the lungs, mediastinal lymph nodes, and spleen of patients with COVID-19 associated lymphopenia. Viruses. 2021;13(7):1410. DOI: 10.3390/V13071410][Godfrey DI, MacDonald HR, Kronenberg M, et al. NKT cells: what’s in a name? Nat Rev. Immunol. 2004;4(3):231–237. DOI: 10.1038/NRI1309][Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–510. DOI: 10.1038/NI1582][Du J, Wei L, Li G, et al. Persistent high percentage of HLA-DR+CD38high CD8+ T cells associated with immune disorder and disease severity of COVID-19. Front Immunol. 2021;12:735125. DOI: 10.3389/fimmu.2021.735125][Zambello R, Barilà G, Manni S, et al. NK cells and CD38: Implication for (immuno)therapy in plasma cell dyscrasias. Cells. 2020;9(3):768. DOI: 10.3390/CELLS9030768][Magnone M, Bauer I, Poggi A, et al. NAD+ levels control Ca2+ store replenishment and Mitogen-induced Increase of Cytosolic Ca2+ by Cyclic ADP-ribose-dependent TRPM2 channel gating in human T lymphocytes. J Biol Chem. 2012;287(25):21067–21081. DOI: 10.1074/JBC.M111.324269][Maucourant C, Filipovic I, Ponzetta A, et al. Natural killer cell immunotypes related to COVID-19 disease severity. Sci Immunol. 2020;5(50):eabd6832. DOI: 10.1126/SCIIMMUNOL.ABD6832][Chini CCS, Peclat TR, Warner GM, et al. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD+ and NMN levels. Nat Metab. 2020;2(11):1284–1304. DOI: 10.1038/s42255-020-00298-z][Schiavoni I, Scagnolari C, Horenstein AL, et al. CD38 modulates respiratory syncytial virus-driven proinflammatory processes in human monocyte-derived dendritic cells. Immunology. 2018;154(1):122–131. DOI: 10.1111/IMM.12873][Zeidler JD, Kashyap S, Hogan KA, Chini EN. Implications of the nadase CD38 in COVID pathophysiology. Physiol Rev. 2022;102:339–341. DOI: 10.1152/PHYSREV.00007.2021][Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–791. DOI: 10.1158/2159-8290.CD-20-0422][Van Eeden C, Khan L, Osman MS, Tervaert JWC. Natural killer cell dysfunction and its role in COVID-19. Int J Mol Sci. 2020;21(17):6351. DOI: 10.3390/IJMS21176351][Menzies FM, Fleming A, Caricasole A, et al. Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities. Neuron. 2017;93:(5):1015–1034. DOI: 10.1016/j.neuron.2017.01.022][Morandi F, Horenstein AL, Chillemi A, et al. CD56brightCD16− NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4+ T Cell proliferation. J Immunol. 2015;195(3):965–972. DOI: 10.4049/jimmunol.1500591][Horenstein AL, Faini AC, Malavasi F. CD38 in the age of COVID-19: Amedical perspective. Physiol Rev. 2021;101(4):1457–1486. DOI: 10.1152/physrev.00046.2020]